1; Paige Marquez1; John Su1; Geoffrey M. Calvert1; Ruiling Liu1; Tanya Myers1; Narayan Nair2; Stacey Martin1; Thomas Clark1; Lauri Markowitz1; Nicole Lindsey1; Bicheng Zhang1; Charles Licata1; Amelia Jazwa1; Mark Sotir1; Tom Shimabukuro1 (View author affiliations)Two COVID-19 vaccines have received Emergency Use Authorization for administration in the United States.
In preauthorization clinical trials, local and systemic reactions were reported; no serious safety problems were detected.Monitoring, conducted as part of the U.S.
vaccination program, indicates reassuring safety profiles for COVID-19 vaccines. Local and systemic reactions were common; rare reports of anaphylaxis were received.